Engineered immune cells take aim at Hard-to-Treat breast cancers

NCT ID NCT07510802

Recruiting now Disease control Sponsor: Beijing Biotech Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new treatment using specially engineered immune cells (CAR-NK cells) that target multiple proteins on breast cancer cells. It is for people with advanced or metastatic breast cancer, including HER2-positive and triple-negative types, who have not responded to standard therapies. Participants receive cells tailored to their tumor's markers after a short course of chemotherapy to prepare the body. The goal is to check safety and see if the treatment can shrink tumors.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm HER2 positive breast carcinoma Neoplasm Metastasis triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER (ADVANCED/METASTATIC) HER2-POSITIVE BREAST CANCER TRIPLE NEGATIVE BREAST CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Peking University Shenzhen Hospital
RECRUITING

Shenzhen, Guangdong, 518036, China

Contact Phone: •••-•••-•••• Email: •••••@•••••